Last viewed:
ALLK
Prices are updated after-hours
ALLK
|
$1.035
-2.36%
190K
|
Health Technology
(0.0% 1d)
(-19.8% 1m)
(-75.1% 1y)
(0.0% 2d)
(0.0% 3d)
(-2.8% 7d)
(-52.7%
volume)
Earnings Calendar: 2024-03-06
Market Cap: $ 90,949,585
http://www.allakos.com
Sec
Filling
|
Patents
| 90 employees
(US) Allakos, Inc. engages in the development of therapeutic antibodies. Its primary product is AK002, a monoclonal antibody used for the treatment of various eosinophil and mast cell related diseases such as eosinophilic gastritis, urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis. The company was founded by Christopher Bebbington, Nenad Tomasevic, Bruce S. Bochner, and Robert Schleimer in 2012 and is headquartered in Redwood City, CA.
antibody
monoclonal antibodies
t-cell
al002
treatment
ceiling
add to watch list
Paper trade
email alert is off
Press-releases
Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
Published: 2024-03-14
(Crawled : 20:00)
- globenewswire.com
ALLK
|
$1.035
-2.36%
190K
|
Health Technology
| -19.54%
| O: -1.15%
H: 2.33%
C: 1.55%
business
year
update
financial
results
Allakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024
Published: 2024-02-26
(Crawled : 12:00)
- globenewswire.com
ALLK
|
$1.035
-2.36%
190K
|
Health Technology
| -22.79%
| O: 2.21%
H: 10.07%
C: 5.04%
ak006
cell
preclinical
Allakos Announces Publication Highlighting AK006 Mast Cell Inhibition
Published: 2024-02-12
(Crawled : 12:00)
- globenewswire.com
ALLK
|
$1.035
-2.36%
190K
|
Health Technology
| -21.64%
| O: 1.49%
H: 10.29%
C: 2.21%
ak006
publication
cell
Allakos Announces a Restructuring to Focus on Development of AK006
Published: 2024-01-16
(Crawled : 12:00)
- globenewswire.com
ALLK
|
$1.035
-2.36%
190K
|
Health Technology
| -64.88%
| O: -59.2%
H: 10.66%
C: -2.46%
ak006
Allakos Announces Phase 2 Lirentelimab Trials in Atopic Dermatitis and Chronic Spontaneous Urticaria Did Not Meet Their Primary Endpoints
Published: 2024-01-16
(Crawled : 12:00)
- globenewswire.com
ALLK
|
$1.035
-2.36%
190K
|
Health Technology
| -64.88%
| O: -59.2%
H: 10.66%
C: -2.46%
urticaria
dermatitis
trials
Allakos Appoints Neil Graham to its Board of Directors
Published: 2023-08-30
(Crawled : 20:00)
- globenewswire.com
REGN
|
$893.67
-0.04%
230K
|
Health Technology
| 7.93%
| O: 0.11%
H: 0.0%
C: -1.12%
ASLN
|
$0.54
20K
|
Health Technology
| -76.59%
| O: 1.9%
H: 0.93%
C: -0.7%
ALLK
|
$1.035
-2.36%
190K
|
Health Technology
| -64.16%
| O: 1.02%
H: 5.17%
C: -2.7%
Allakos Appoints Rand Sutherland and Dolca Thomas to its Board of Directors
Published: 2023-08-02
(Crawled : 20:00)
- globenewswire.com
SNYNF
|
News
|
$92.7
600K
|
Health Technology
| -10.05%
| O: -1.6%
H: 0.11%
C: 0.11%
TBIO
|
News
|
$0.303
-8.46%
140K
|
Health Technology
| -70.41%
| O: -0.69%
H: 0.0%
C: 0.0%
SNY
|
News
|
$46.545
2.55%
2.3M
|
Health Technology
| -12.72%
| O: -3.79%
H: 0.0%
C: 0.0%
KRYS
|
$158.87
-3.11%
140K
|
Health Technology
| 31.5%
| O: -2.31%
H: 0.73%
C: -1.14%
EQ
|
$1.715
-0.87%
89K
|
Health Technology
| 146.67%
| O: 9.59%
H: 7.68%
C: -6.75%
KDNY
|
$40.39
0.22%
-0.17%
0
|
Health Technology
| 0.5%
| O: 0.02%
H: 0.26%
C: 0.22%
ALLK
|
$1.035
-2.36%
190K
|
Health Technology
| -80.87%
| O: -0.91%
H: 1.84%
C: -1.1%
Allakos Presents Preclinical Data at EAACI Hybrid Congress 2023 Highlighting Lirentelimab and AK006 Mechanisms of Mast Cell Inhibition
Published: 2023-06-12
(Crawled : 11:00)
- globenewswire.com
ALLK
|
$1.035
-2.36%
190K
|
Health Technology
| -78.13%
| O: 0.0%
H: 5.21%
C: 2.71%
ak006
cell
preclinical
Allakos Announces Upcoming Presentation on Lirentelimab and AK006 Mast Cell Inhibition at the European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2023
Published: 2023-06-05
(Crawled : 11:00)
- globenewswire.com
ALLK
|
$1.035
-2.36%
190K
|
Health Technology
| -80.0%
| O: 0.0%
H: 0.95%
C: -2.29%
ak006
presentation
cell
immunology
Allakos Provides Business Update and Reports First Quarter 2023 Financial Results
Published: 2023-05-09
(Crawled : 20:00)
- globenewswire.com
ALLK
|
$1.035
-2.36%
190K
|
Health Technology
| -75.64%
| O: 0.46%
H: 5.54%
C: -0.92%
business
update
financial
results
See all
Last 15 days Sec forms
File Id
Form
Published Date
Transaction Date
Direction
Code
Amount Transacted
Owned Amount